公开(公告)号：US20240294541A1

公开(公告)日：2024-09-05

申请号：US18681141

申请日：2022-08-05

申请人： FILECLO SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA

发明人： Dominika CZERWONKA ,  Julia KRZYWIK ,  Tomasz SOBIERAJSKI ,  Greta KLEJBOROWSKA ,  Malgorzata ULLRICH ,  Witold MOZGA ,  Adam HUCZYNSKI ,  Przemyslaw PILASZEK

IPC分类号： C07D493/20 ,  A61K31/351 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4433 ,  A61K31/453 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/64 ,  A61P35/00

CPC分类号： C07D493/20 ,  A61K31/351 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4433 ,  A61K31/453 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/64 ,  A61P35/00

摘要： The invention relates to compounds constituting C20-N-modified salinomycin derivatives, a method for obtaining the same, a composition containing the same, and their use as a medicament, particularly as an anti-cancer agent.

公开(公告)号：US11957687B2

公开(公告)日：2024-04-16

申请号：US17622454

申请日：2020-07-01

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Joseph Vacca

IPC分类号： A61K31/5377 ,  A61K31/4412 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/513 ,  A61P1/16 ,  C07D213/82 ,  C07D239/36 ,  C07D239/56 ,  C07D295/135 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D498/04 ,  C07D513/04

CPC分类号： A61K31/5377 ,  A61K31/4412 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/513 ,  A61P1/16 ,  C07D213/82 ,  C07D239/36 ,  C07D239/56 ,  C07D295/135 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D498/04 ,  C07D513/04

摘要： The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

公开(公告)号：US20230404986A1

公开(公告)日：2023-12-21

申请号：US18311815

申请日：2023-05-03

申请人： Jeffrey K. HARRISON ,  ChemoCentryx, Inc.

发明人： James J. CAMPBELL ,  Rajinder SINGH ,  Jeffrey K. HARRISON

IPC分类号： A61K31/4433 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K31/496

CPC分类号： A61K31/4433 ,  C07K16/2827 ,  A61K39/39533 ,  A61P35/00 ,  C07K16/2818 ,  A61K31/496

摘要： The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of a central nervous system cancer.

公开(公告)号：US11806337B2

公开(公告)日：2023-11-07

申请号：US17875216

申请日：2022-07-27

申请人： Sanford Burnham Prebys Medical Discovery Institute

发明人： Stephen Gardell ,  Anthony B. Pinkerton ,  Eduard Sergienko ,  Hampton Sessions

IPC分类号： A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

CPC分类号： A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/417 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4355 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

摘要： Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

公开(公告)号：US20230181549A1

公开(公告)日：2023-06-15

申请号：US18163055

申请日：2023-02-01

申请人： Epizyme, Inc.

发明人： Scott DAIGLE ,  Kat COSMOPOULOS

IPC分类号： A61K31/4412 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/55 ,  C07K16/28

CPC分类号： A61K31/4412 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/55 ,  C07K16/2827 ,  C07K2317/76

摘要： The disclosure provides methods of treating, identifying and/or selecting for treatment a subject having a cancer in which an immune checkpoint protein is upregulated. In certain embodiments, the methods for treating cancer in a subject in need thereof comprise administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

公开(公告)号：US20230116770A1

公开(公告)日：2023-04-13

申请号：US17875216

申请日：2022-07-27

申请人： Sanford Burnham Prebys Medical Discovery Institute

发明人： Stephen GARDELL ,  Anthony B. PINKERTON ,  Eduard SERGIENKO ,  Hampton SESSIONS

IPC分类号： A61K31/4409 ,  A61K31/196 ,  A61K31/245 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/422 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/47 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/5386 ,  C07C275/42 ,  C07D213/40 ,  C07D213/56 ,  C07D213/643 ,  C07D213/73 ,  C07D213/74 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D249/04 ,  C07D261/08 ,  C07D263/32 ,  C07D277/28 ,  C07D401/06 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D498/08

摘要： Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.

公开(公告)号：US20230115867A1

公开(公告)日：2023-04-13

申请号：US18072752

申请日：2022-12-01

申请人： Kowa Company, Ltd.

发明人： Ryu OSHIMA ,  Masatoshi ITO ,  Chisato NAGAI

IPC分类号： A61K31/423 ,  A61K31/34 ,  A61K31/4152 ,  A61K31/427 ,  A61K31/4353 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/513 ,  A61K31/7034 ,  A61K38/13 ,  A61P3/06 ,  A61K31/7048

摘要： To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereitiafter also referred to as pemafiterate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pernafiterate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

公开(公告)号：US20230027952A1

公开(公告)日：2023-01-26

申请号：US17779476

申请日：2020-11-23

申请人： INVENTISBIO CO., LTD.

发明人： Xing DAI ,  Yueheng JIANG ,  Yanqin LIU

IPC分类号： C07D405/12 ,  A61K45/06 ,  A61K31/4433 ,  A61P35/00 ,  A61P31/10

摘要： Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to IDO inhibitors, in particular, Compound 1,1-(5-((4-chlorophenyl)amino)-6-(ethyl(tetrahydro-2H-pyran-4-yl)amino)pyridin-3-yl)cyclobu tane-1-carboxylic acid. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

公开(公告)号：US20230027929A1

公开(公告)日：2023-01-26

申请号：US17773404

申请日：2020-11-05

申请人： Dermira, Inc.

发明人： Ferda Cevikbas ,  Christopher Pearson ,  Donnya Etheridge ,  Laura Gleave ,  Mark Duggan ,  Nina Connelly Ursinyova ,  Vasileios Roumpelakis

IPC分类号： C07D213/75 ,  A61K31/4412 ,  A61K31/4433 ,  C07D405/12 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4439 ,  C07D401/12 ,  A61K31/4427 ,  C07D413/04 ,  C07D241/20 ,  A61K31/4965 ,  A61K31/436 ,  C07D498/04 ,  C07D239/47 ,  A61K31/513 ,  A61K31/506 ,  C07D403/12 ,  C07D403/04 ,  C07D401/06 ,  A61K9/00

摘要： The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically or orally acceptable carrier for administration.

公开(公告)号：US11491133B2

公开(公告)日：2022-11-08

申请号：US16991771

申请日：2020-08-12

申请人： Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

发明人： Carrie A. Bowen ,  Douglas F. Burdi ,  Michele L. R. Heffernan ,  Lee W. Herman ,  Linghong Xie

IPC分类号： A61K31/352 ,  A61P25/28 ,  A61P25/24 ,  A61P25/08 ,  A61P25/16 ,  C07D413/04 ,  C07D417/04 ,  C07D405/04 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/42 ,  A61K31/427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/497 ,  A61K31/506

摘要： Compounds of Formula I are described as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need are also disclosed.